Drug Profile
Cefepime/Zidebactam - Wockhardt
Alternative Names: WCK-5222; Zaynich; Zidebactam/cefepime intravenous - WockhardtLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Wockhardt
- Developer IQVIA; Wockhardt
- Class Antibacterials; Azabicyclo compounds; Cephalosporins; Piperidines; Small molecules; Sulfoxides
- Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Urinary tract infections
- No development reported Gram-negative infections
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Gram-negative-infections in USA (SC)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in USA (IV, Infusion)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Gram-negative-infections in India (IV, Infusion)